Patents by Inventor Mark W. Holladay

Mark W. Holladay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-Pyridyl enantiomers and their use as analgesics
    Patent number: 6133253
    Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: ##STR1## or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.
    Type: Grant
    Filed: December 9, 1997
    Date of Patent: October 17, 2000
    Assignee: Abbott Laboratories
    Inventors: Mark W. Holladay, Stephen P. Arneric, Hao Bai, Michael J. Dart, Nan-Horng Lin, John K. Lynch, Yat Sun Or, Keith B. Ryther, James P. Sullivan, James T. Wasicak, Paul P. Ehrlich
  • 3-Pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
    Patent number: 6127386
    Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds of the formula: ##STR1## or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission. Key intermediates and processes using this key intermediates to produce compounds of formula I with the variables defined in the specification are also described.
    Type: Grant
    Filed: April 18, 1997
    Date of Patent: October 3, 2000
    Assignee: Abbott Laboratories
    Inventors: Nan-Horng Lin, Yun He, Mark W. Holladay, Keith B. Ryther, Yihong Li, Hao Bai
  • Furopyridine, thienopyridine pyrrolopyridine useful in controlling chemical synaptic transmission
    Patent number: 6001849
    Abstract: Novel heterocyclic ether compounds having the formula: ##STR1## wherein A, m, R, X, Y.sup.1, Y.sup.2 and Y.sup.3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: December 14, 1999
    Assignee: Abbott Laboratories
    Inventors: Richard L. Elliott, Keith B. Ryther, Mark W. Holladay, James T. Wasicak, Jerome F. Daanen, Nan-Horng Lin, Michael J. Dart, Yun He, Yihong Li
  • 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
    Patent number: 5948793
    Abstract: Novel heterocyclic ether compounds of the formula: ##STR1## wherein n, *, R.sup.1, R.sup.2, R.sup.3 and y are specifically defined, or pharmaceutically acceptable salts or prodrugs thereof, which are useful in selectively controlling neurotransmitter release; therapeutically-effective pharmaceutical compositions of these compounds; and use of said compositions to selectively control neurotransmitter release in mammals.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 7, 1999
    Assignee: Abbott Laboratories
    Inventors: Melwyn A. Abreo, David E. Gunn, Nan-Horng Lin, David S. Garvey, Mark W. Holladay, Keith B. Ryther
  • Heterocyclic ether compounds useful in controlling neurotransmitter release
    Patent number: 5914328
    Abstract: Novel heterocyclic ether compounds of the formula: ##STR1## wherein *, A,B, n, R.sup.1, R.sup.2 and X are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are useful in selectively activating or inhibiting neurotransmitter release; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to activate or inhibit neurotransmitter release in mammals.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 22, 1999
    Assignee: Abbott Laboratories
    Inventors: Nan-Horng Lin, Mark W. Holladay, Melwyn A. Abreo, David E. Gunn, Suzanne A. Lebold, Richard L. Elliott, Yun He
  • 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
    Patent number: 5733912
    Abstract: 7a-Substituted hexahydro-1H-pyrrolizine compounds having the formula ##STR1## wherein A is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to selectively control synaptic transmission in mammals.
    Type: Grant
    Filed: February 19, 1997
    Date of Patent: March 31, 1998
    Assignee: Abbott Laboratories
    Inventors: James T. Wasicak, David S. Garvey, Mark W. Holladay, Nan-Horng Lin, Keith B. Ryther
  • 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
    Patent number: 5629325
    Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds of the formula: ##STR1## or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission.
    Type: Grant
    Filed: June 6, 1996
    Date of Patent: May 13, 1997
    Assignee: Abbott Laboratories
    Inventors: Nan-Horng Lin, Yun He, Mark W. Holladay, Keith Ryther, Yihong Li
  • 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
    Patent number: 5472958
    Abstract: Selective and potent cholinergic ligands selective for neuronal nicotinic cholinergic channel receptors, which ligands have the formula: ##STR1## as well as pharmaceutically-acceptable salts or prodrugs thereof, which are useful in the treatment of dementias, attentional hyperactivity disorder, or substance abuse withdrawal characterized by decreased cholinergic function, one of which is also an analgesic agent, and one of which is an agent useful for treating anxiety associated with cognitive impairment.
    Type: Grant
    Filed: August 29, 1994
    Date of Patent: December 5, 1995
    Assignee: Abbott Laboratories
    Inventors: David E. Gunn, Jr., Richard L. Elliott, Nan-Horng Lin, Hana A. Kopecka, Mark W. Holladay
  • Amino acid analog CCK antagonists
    Patent number: 5346907
    Abstract: Analogs of CCK-tetrapeptides, which analogs have the formula ##STR1## wherein A, B, D, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are specifically defined, having activity as CCK antagonists, useful in the treatment or prevention of disorders of the gastrointestinal, central nervous, appetite regulating or pain regulating systems.
    Type: Grant
    Filed: February 16, 1993
    Date of Patent: September 13, 1994
    Assignee: Abbott Laboratories
    Inventors: James F. Kerwin, Jr., Mark W. Holladay, Michael J. Bennett
  • Peptide analog type-B CCK receptor ligands
    Patent number: 5340802
    Abstract: Peptide analog type-B CCK receptor ligands or pharmaceutically-acceptable salts thereof, which are useful for treating central nervous system disorders, substance abuse, gastrointestinal disorders, endocrine disorders, eating-related disorders and for the treatment of shock, respiratory and cardiocirculatory insufficiencies.
    Type: Grant
    Filed: January 29, 1993
    Date of Patent: August 23, 1994
    Assignee: Abbott Laboratories
    Inventors: Kazumi Shiosaki, Alex M. Nadzan, David S. Garvey, Youe-Kong Shue, Mark S. Brodie, Mark W. Holladay, John Y.-L. Chung, Michael D. Tufano, Paul D. May
  • Derivatives of tetrapeptides as CCK agonists
    Patent number: 5270302
    Abstract: Selective and potent Type-A CCK receptor agonists of formula (I):X--Y--Z--Q (I)or a pharmaceutically acceptable salt thereof, wherein,X is selected from ##STR1## Y is selected from ##STR2## Z is ##STR3## and Q is ##STR4## or pharmaceutically-acceptable salts thereof, useful in the treatment of gastrointestinal disorders (including gallbladder disorders), central nervous system disorders, insulin-related disorders and pain, as well as in appetite regulation.
    Type: Grant
    Filed: June 17, 1991
    Date of Patent: December 14, 1993
    Assignee: Abbott Laboratories
    Inventors: Kazumi Shiosaki, Alex M. Nadzan, Hana Kopecka, Youe-Kong Shue, Mark W. Holladay, Chun W. Lin, Hugh N. Nellans